Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Renovo Plc. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (37)	12/13/2007 5:24:52 PM
From: keokalani'nui	Respond to of 40

They also said worst case the mole market is 2%. And realistically the keloid trial is in the HnN area and doesn't suffer from same problems mole trial did; thus how likely is it a label would say "not effective above the shoulders". Overall, the thing that bothers me the most is that it looks to be just 33% effective. 1/3 no improvement, 1/3 mild, 1/3 moderate and major. Could explain Shire in the US. Not that it should make anyone feel better, 2007 has been a bad year relative-to-index for me.